796 results on '"Trusolino, Livio"'
Search Results
2. XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients
3. Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer
4. Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer
5. Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification
6. Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer
7. Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
8. Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity
9. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
10. Towards precision oncology with patient-derived xenografts
11. Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia
12. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
13. TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer
14. Effective drug combinations in breast, colon and pancreatic cancer cells
15. Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin
16. The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation
17. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
18. Precision oncology in metastatic colorectal cancer — from biology to medicine
19. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
20. Supplementary Figure 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
21. Supplementary Table 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
22. Supplementary Table 8 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
23. Supplementary Table 5 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
24. Supplementary Figure 5 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
25. Supplementary Table 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
26. Supplementary Table 9 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
27. Supplementary Table 7 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
28. Supplementary Figure 6 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
29. Supplementary Table 3 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
30. Supplementary Methods 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
31. Supplementary Figure 3 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
32. Supplementary Table 6 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
33. Supplementary Figure 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
34. Supplementary Table 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
35. Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
36. Data from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
37. Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer
38. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling
39. Adaptive mutability of colorectal cancers in response to targeted therapies
40. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
41. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga
42. Pathway level subtyping identifies a slow-cycling and transcriptionally lethargic biological phenotype associated with poor clinical outcomes in colon cancer independent of genetics
43. Abstract B005: Tolerance to colibactin correlates with response to chemotherapeutic agents in colorectal cancer
44. Resistance of Colorectal Tumors to Anti-EGFR Antibodies
45. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
46. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
47. β4 Integrin Activates a Shp2-Src Signaling Pathway That Sustains HGF-Induced Anchorage-Independent Growth
48. Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer
49. Innovations, challenges, and minimal information for standardization of humanized mice
50. Growth Factor-Dependent Activation of αvβ3 Integrin in Normal Epithelial Cells: Implications for Tumor Invasion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.